Adlai Nortye director Ji Ping sells $83,150 in shares
On September 22, 2026, director Ji Ping of Adlai Nortye Group Ltd. (ANL) divested 5,000 shares of the company's stock, selling them at $16.63 per share, resulting in a total of $83,150. Despite ANL shares having increased by over 800% in the last year, the stock currently trades at $15.53, lower than Mr. Ji's transaction price. Following the sale, Ji Ping retains 131,667 American Depository shares in ANL.
Analysts suggest the company may be overvalued, with a market cap of $1.02 billion despite ongoing losses. Meanwhile, Adlai Nortye Ltd. initiated a clinical trial in the United States for its drug AN9025, which targets solid tumors with RAS mutations. Jefferies and Lucid Capital Markets both initiated buy ratings for ANL, with price targets of $31.00 and $49.00, respectively.
The company has also bolstered its Scientific Advisory Board with oncologists Dr. David S. Hong and Dr. Piro Lito, enhancing its drug pipeline and scientific capabilities.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
